更新于：2024-11-01

Internal hemorrhoids

内痔

更新于：2024-11-01

基本信息

别名

HEMORRHOID INTERNAL、Hemorrhoids, internal、Internal Hemorrhoid

+ [18]

简介

A hemorrhoid which originates above the dentate line.

关联

项与内痔相关的药物

MaYingLongShexiangZhiChuang

马应龙麝香痔疮膏

靶点-

作用机制-

在研机构

马应龙药业集团股份有限公司

原研机构

马应龙药业集团股份有限公司

在研适应症

痔疮 [+3]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期1983-01-01

Phenol

苯酚

靶点-

作用机制-

在研机构-

原研机构-

在研适应症-

非在研适应症

内痔

最高研发阶段批准上市

首次获批国家/地区-

首次获批日期1800-01-20

Wuwei Huazhi Capsule

五味化痔胶囊

靶点-

作用机制-

在研机构

石家庄藏诺生物科技有限公司

原研机构

石家庄藏诺生物科技有限公司

在研适应症

内痔 [+1]

非在研适应症-

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期1800-01-20

项与内痔相关的临床试验

ChiCTR2400087765 / RecruitingIIT

A single-center study on the treatment of hemorrhagic internal hemorrhoids with endoscopic sclerotherapy and classic hemorrhoidectomy based on LrDRf classification

开始日期2024-08-04

申办/合作机构-

NCT06106269 / RecruitingN/AIIT

Hemorrhoidal Embolization Trial-1 (HEMBO-1)

This study will assess how effective and safe rectal artery embolization works to treat symptomatic bleeding predominant internal hemorrhoids.

开始日期2024-06-07

申办/合作机构

Mayo Clinic

[+1]

NCT06363513 / Not yet recruitingN/AIIT

The Efficacy of Aescin in Combination With Micronized Purified Flavonoid Fraction (MPFF) in the Early Control of Bleeding From Acute Internal Hemorrhoids, A Randomized Controlled Trial

Hemorrhoidal disease, characterized by symptomatic enlargement and distal displacement of anal cushions, has been a subject of recognition and management for centuries. The etymology of "hemorrhoid" is traced back to the Greek words haima (blood) and rhoos (flow). Prevalent in over 20% of the population across various life stages, this anorectal condition impacts both genders. The multifaceted development of the disease incorporates theories encompassing abnormal dilation of hemorrhoidal plexuses, distension of arteriovenous anastomoses, prolapse of anal pads, and a myriad of genetic, anatomical, dietary, and lifestyle factors. Manifestations range from venous distension to bleeding and thrombosis, with classification based on location (internal/external/combined) and degree of prolapse (grade 1-4).
Upon comprehensive history-taking and examinations, including digital rectal and proctoscope assessments, a definitive diagnosis is established, leading to the treatment phase. Although outpatient procedures demonstrate efficacy, patients may persist with pain and discomfort. Medical intervention assumes significance for stages 1 and 2, incorporating approaches such as rubber-band ligation, injection sclerotherapy, and dietary modifications. Micronized Purified Flavonoid Fraction (MPFF), integral to hemorrhoid treatment, has been scrutinized for its ability to mitigate pathogenic processes culminating in acute bleeding. The stagnation of blood in vascular plexuses prompts an inflammatory response, activating white cells and increasing vessel wall permeability. MPFF's flavonoid compounds are posited to alleviate bleeding by augmenting venous tone, reducing stasis, inhibiting inflammatory mediators, and enhancing lymphatic drainage[8]. Multiple trials substantiate MPFF's efficacy in ceasing bleeding, alleviating symptoms, and preventing hemorrhoid relapse.
Aescin, a saponin mixture found in Aesculus hippocastanum (horse chestnut). The primary active component, β-aescin, contributes to the plant's medicinal attributes. Experimental investigations in animal models underscore its anti-edematous, anti-inflammatory, and venotonic properties, attributed to molecular mechanisms facilitating ion entry into channels and elevating venous tension. While the therapeutic benefits of aescin for hemorrhoids are acknowledged, the absence of randomized control trials impedes the conclusive validation of its efficacy. In the realm of diverse treatment options, this proposed randomized controlled trial aims to assess the comparative effectiveness of combining aescin with MPFF versus MPFF alone in managing hemorrhoid-related symptoms. The study aspires to furnish valuable insights for refining therapeutic strategies in the management of hemorrhoids and enhancing patient outcomes.

开始日期2024-04-01

申办/合作机构

Chiang Mai University

100 项与内痔相关的临床结果

登录后查看更多信息

100 项与内痔相关的转化医学

登录后查看更多信息

0 项与内痔相关的专利（医药）

登录后查看更多信息

698

项与内痔相关的文献（医药）

2024-10-11·The American journal of case reports

Iron-Related Pseudomelanosis Duodeni in a Patient with Gastrointestinal Bleeding: A Case Report.

Article

作者: Chebbo, Houssein ; El Hajj, Ihab I ; Saleh, Sarah ; Karam, Karam

BACKGROUND Pseudomelanosis duodeni (PD) is a rare incidental endoscopic finding characterized by flat, discrete speckles of dark pigment, usually in the proximal duodenum. PD is associated with chronic conditions, including end-stage renal disease, hypertension, and diabetes, and with certain medications, including oral iron supplements and sulfur-containing antihypertensives. CASE REPORT A 56-year-old woman presented with lower abdominal pain, intermittent rectorragia, and a history of peptic ulcer disease and iron-deficiency anemia, treated with oral iron supplements. She was hemodynamically stable, and laboratory test results were pertinent only for microcytic anemia. In the workup of iron-deficiency anemia, esophagogastroduodenoscopy was performed, showing findings suspicious for PD, which was confirmed by pathology. Colonoscopy revealed large internal hemorrhoids, and hemorroidectomy was scheduled during the same admission. Duodenum biopsies showed edematous villosities and large clusters of pigmented macrophages, with golden-brown cytoplasm positively stained with Perl's Prussian blue stain, indicating the presence of iron inside the macrophages. These findings confirmed the PD diagnosis. The pigment in PD is composed primarily of iron and sulfur, with iron being the main component, as seen in staining. In our case, we present findings of PD along with lower gastrointestinal bleeding manifesting as hemmoroidal bleeding. Giving the anatomical nature of hemorrhoids and that our patient was on oral iron therapy, the most likely mechanism behind the development of PD in our case was related to the oral iron therapy. CONCLUSIONS PD is a benign disorder of the duodenum. Further studies are needed to investigate its long-term outcomes and to formulate optimal management strategies.

2024-10-01·Gastrointestinal Endoscopy

Application of iodine staining in endoscopic ligation for internal hemorrhoids: Where exactly is the anorectal line?

Article

作者: Guan, Fu ; Wang, Shengbing ; Zhuo, Qingqing ; Wen, Pingwu

2024-10-01·Colorectal Disease

Global treatment of haemorrhoids—A worldwide snapshot audit conducted by the International Society of University Colon and Rectal Surgeons

Article

作者: Lohsiriwat, Varut ; Sah, Bikash ; Nunoo‐Mensah, Joseph ; Cerkauskaite, Dovile ; Gupta, Rakesh Kumar ; Kumar, Abhijeet ; Fortunato, Richard ; Samalavicius, Narimantas E. ; Dulskas, Audrius ; Khanal, Bhawani

AbstractAimThere is no universally accepted treatment consensus for haemorrhoids, and thus, management has been individualized all over the world. This study was conducted to assess a global view of how surgeons manage haemorrhoids.MethodsThe research panel of the International Society of University Colon and Rectal Surgeons (ISUCRS) developed a voluntary, anonymous questionnaire evaluating surgeons' experience, volume and treatment approaches to haemorrhoids. The 44 multiple‐choice questionnaire was available for one month via the ISUCRS email database and the social media platforms Viber and WhatsApp.ResultsThe survey was completed by 1005 surgeons from 103 countries; 931 (92.6%) were in active practice, 819 (81.5%) were between 30 and 60 years of age, and 822 (81.8%) were male. Detailed patient history (92.9%), perineal inspection (91.2%), and digital rectal examination (91.1%) were the most common assessment methods. For internal haemorrhoids, 924 (91.9%) of participants graded them I–IV, with the degree of haemorrhoids being the most important factor considered to determine the treatment approach (76.3%). The most common nonprocedural/conservative treatment consisted of increased daily fibre intake (86.9%), increased water intake (82.7%), and normalization of bowel habits/toilet training (74.4%). Conservative treatment was the first‐line treatment for symptomatic first (92.5%), second (72.4%) and third (47.3%) degree haemorrhoids; however, surgery was the first‐line treatment for symptomatic fourth degree haemorrhoids (77.6%). Rubber band ligation was the second‐line treatment in first (50.7%) and second (47.2%) degree haemorrhoids, whereas surgery was the second‐line treatment in third (82.9%) and fourth (16.7%) degree symptomatic haemorrhoids. Rubber band ligation was performed in the office by 645(64.2%) of the participants. The most common surgical procedure performed for haemorrhoids was an excisional haemorrhoidectomy for both internal (87.1%) and external (89.7%) haemorrhoids – with 716 (71.2%) of participants removing 1, 2 or 3 sectors as necessary.ConclusionAlthough there is no global haemorrhoidal treatment consensus, there are many practice similarities among the different cultures, resources, volume and experience of surgeons around the world. With additional studies, a consensus statement could potentially be developed.

项与内痔相关的新闻（医药）

2023-11-02

·BioSpace

Maxwell Biosciences Announces Promising Activity of Claromer Compound Against Ebola Virus in a Research Study

Austin, Texas--(News - November 2, 2023) - Maxwell Biosciences, Inc., (MXB) a pre-clinical drug platform company focused on developing biomimetic therapeutics that improve upon natural immune system peptides based on its patented Claromer® technology platform, today announced that it has received promising data on activity against Ebola virus from a study conducted in collaboration with NIH-NIAID's Rocky Mountain Laboratories (RML). RML is one of the few Biosafety Level (BSL) 4 labs in the United States with the capability to do this work. The data showed one of Maxwell's Claromer compounds is active against Ebola virus within the critical time frame required to address Ebola virus disease progression. Once a human is infected, Ebola virus disease can be lethal within 4-5 days. The data shows how the Claromer compound is able to inhibit the virus's growth for up to 72 hours at a lower concentration and up to 96 hours at a higher concentration. This is a world-first breakthrough for Maxwell's small molecule drug candidate - currently, only monoclonal antibody products are licensed with activity against one ebolavirus strain, Zaire ebolavirus. "Ebola virus has caused serious global outbreaks and due to its virulence and case mortality. Yet to date there is no effective small molecule drug for the virus," said J. Scotch McClure, Maxwell's CEO. McClure continued: "I'm gratified for the support from the researchers at NIH-NIAID's RML for their efforts to prepare for future outbreaks." Maxwell is currently developing its Claromer drug platform, which has the potential to replace almost all antibiotics, antifungals and antivirals. Ebola virus disease (EVD) is highly contagious and life-threatening, causing symptoms of fever, tiredness, headache, diarrhea, vomiting, as well as external and internal hemorrhage. It can quickly progress to multi-organ system failure, shock, then death. Even with the newest treatments available, Ebola virus disease has a greater than 30% fatality rate, with the average case fatality rate remaining at about 50%. Since the first outbreak in Africa in 1976, several outbreaks and epidemics of Ebola virus have occurred in Western and Central Africa. About Maxwell Biosciences Founded in 2016, Maxwell Biosciences is a pre-clinical drug platform company that develops biomimetic therapeutics - synthetic compounds that mimic and improve upon natural immune system peptides. Inspired by nature, these small molecules have been shown to be effective against Ebola, pan-coronavirus, pan-Influenza A (avian, swine, and human) in destroying not just viruses, but also all tested bacteria, fungi and biofilms with a single compound, while safely avoiding healthy cells. This "One Drug for Many Bugs" technology has been shown to be well-tolerated in human tissues in vitro, and in multiple animal studies, are shelf-stable and do not require a cold-chain. The compounds imitate key components of the immune system, humanity's greatest asset in fighting disease. Maxwell's technology is protected by numerous granted and pending patents and is led by a world-class team of scientists, military veterans, and experienced life science executives. To learn more about Maxwell Biosciences, visit MaxwellBiosciences.com, or follow us on X. Contact Info: 1-855-629-2461; investor.relations@maxwellbiosciences.com The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred. To view the source version of this press release, please visit

临床研究